Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
TScan Therapeutics, Inc. (TCRX) had Debt to Equity Ratio of 0.26 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$2.57M |
|
$-22.98M |
|
-- |
|
$2.57M |
|
$26.43M |
|
$-23.86M |
|
$0.88M |
|
$-22.98M |
|
$-22.98M |
|
$-22.98M |
|
$-22.98M |
|
$-22.98M |
|
$-22.98M |
|
$-23.86M |
|
$-23.14M |
|
129.78M |
|
129.78M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$157.21M |
|
$8.71M |
|
$71.58M |
|
$228.79M |
|
$18.70M |
|
$32.53M |
|
$86.97M |
|
$105.67M |
|
$123.12M |
|
$123.12M |
|
$123.12M |
|
56.90M |
|
| Cash Flow Statement Financials | |
$-135.32M |
|
$109.37M |
|
$-0.34M |
|
$183.72M |
|
$157.44M |
|
$-26.28M |
|
$11.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.41 |
|
-- |
|
-- |
|
0.21 |
|
|
Debt to Equity Ratio |
0.26 |
100.00% |
|
-929.41% |
|
-929.41% |
|
-- |
|
-895.09% |
|
-895.09% |
|
$-139.73M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-18.66% |
|
-18.66% |
|
-10.04% |
|
-14.76% |
|
$2.16 |
|
$-1.08 |
|
$-1.04 |
|